Clinical predictors of response to clozapine in patients with Treatment Resistant Schizophrenia

Psychopharmacology Bulletin

Volumn 44, Issue 3, 2011, Pages 4-

  Rajkumar, A P ^a,b   Chitra, C ^a   Bhuvaneshwari, S ^a   Poonkuzhali, B ^a   Kuruvilla, A K ^a   Jacob, K S ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Catatonia; Clozapine; Psychopathology; Schizophrenia; Smoking

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CASE CONTROL STUDY; CATATONIA; COGNITIVE DEFECT; DEMOGRAPHY; DISABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIFE EVENT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PSYCHOTRAUMA; RISK ASSESSMENT; SCHIZOPHRENIA; SMOKING; SOMNOLENCE; TREATMENT RESPONSE;

EID: 84863549349     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. Sep 1988;45(9):789-796.
2. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. Jan 2003;60(1):82-91.
3. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res. Nov 15 2005;79(2/3):145-155.
4. Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs. 2005;19(10):843-872.
5. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. Jun 2000;157(6):975-981.
6. Chung C, Remington G. Predictors and markers of clozapine response. Psychopharmacology (Berl). May 2005;179(2):317-335.
7. Mancama D, Arranz MJ, Kerwin RW. Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs. 2002;16(5):317-324.
8. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet. May 6 2000;355(9215):1615-1616.
9. Hwang R, Shinkai T, De Luca V, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl). Aug 2005;181(1):179-187.
10. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics. Apr 2010;20(4):274-276.
11. Lieberman JA, Kane JM, Safferman AZ, et al. Predictors of response to clozapine. J Clin Psychiatry. Sep 1994;(Suppl B55):126-128.
12. Gross A, Joutsiniemi SL, Rimon R, Appelberg B. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. Pharmacopsychiatry. May 2004;37(3):119-122.
13. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull. Nov 2008;34(6):1130-1144.
14. Kelly DL, Feldman S, Boggs DL, Gale E, Conley RR. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Compr Psychiatry. May-Jun 2010;51(3):298-302.
15. Honer WG, MacEwan GW, Kopala L, et al. A clinical study of clozapine treatment and predictors of response in a Canadian sample. Can J Psychiatry. May 1995;40(4):208-211.
16. Umbricht DS, Wirshing WC, Wirshing DA, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry. May 2002;63(5):420-424.
17. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. Dec 1994;151(12):1744-1752.
18. Mauri MC, Volonteri LS, Dell'Osso B, et al. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol. Dec 2003;23(6):660-664.
19. Ciapparelli A, Ducci F, Carmassi C, et al. Predictors of response in a sample of treatment-resistant psychotic patients on clozapine. Eur Arch Psychiatry Clin Neurosci. Oct 2004;254(5):343-346.
20. Ng CH, Chong SA, Lambert T, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol. May 2005;20(3):163-168.
21. Semiz UB, Cetin M, Basoglu C, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. Aug 15 2007;31(6):1330-1336.
22. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799-812.
23. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare; 1976.
24. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. Nov2006;21(11):1078-1085.
25. WHO. WHODAS II Disability Assessment Schedule: 12-Item Interviewer Administered Version. Geneva: World Health Organization; 2001.
26. Chopra PK, Couper JW, Herrman H. The assessment of patients with long-term psychotic disorders: application of the WHO Disability Assessment Schedule II. Aust N Z J Psychiatry. Sep 2004;38(9):753-759.
27. Pennebaker JW, Susman JR. Disclosure of traumas and psychosomatic processes. Soc Sci Med. 1988;26(3):327-332.
28. Rabinowitz J, Levine SZ, Brill N, Bromet EJ. The premorbid adjustment scale structured interview (PAS-SI): preliminary findings. Schizophr Res. Feb 2007;90(1/3):255-257.
29. Wongsinsup C, Taesotikul W, Kaewvichit S, Sangsrijan S, Sangsrija S. Determination of Clozapine in Human Plasma by High-Performance Liquid Chromatography with UV-VIS Detector. CMU. J. Nat. Sci. 2010;9:29-37.
30. Conley RR, Carpenter WT, Jr., Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry. Sep 1997;154(9):1243-1247.
31. Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J. When symptoms persist: clozapine augmentation strategies. Schizophr Bull. 2001;27(4):615-628.
32. Ragin C. Constructing Social Research: Pine Forge Press, Sage publications; 1994.
33. Fabrazzo M, La Pia S, Monteleone P, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology. Dec 2002;27(6):1050-1055.
34. Estellat C, Torgerson DJ, Ravaud P. How to perform a critical analysis of a randomised controlled trial. Best Pract Res Clin Rheumatol. Apr 2009;23(2):291-303.
35. Burns T. Evolution of outcome measures in schizophrenia. Br J Psychiatry Suppl. Aug 2007;50:s1-6.
36. Honigfeld G, Patin J. Predictors of response to clozapine therapy. Psychopharmacology (Berl). 1989;99 Suppl:S64-67.
37. Rosenheck R, Lawson W, Crayton J, et al. Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Biol Psychiatry. Sep 15 1998;44(6):475-482.
38. Pickar D, Owen RR Jr., Litman RE, Hsiao JK, Su TP. Predictors of clozapine response in schizophrenia. J Clin Psychiatry. Sep 1994;(Suppl B55):129-132.
39. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. Dec 2003;60(12):1187-1192.
40. Jerling M, Merle Y, Mentre F, Mallet A. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol. Nov 1997;44(5):447-453.
41. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. Sep 2007;32(9):1903-1910.
42. Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull. Mar 2010;36(2):239-242.
43. Paparrigopoulos T, Tzavellas E, Ferentinos P, Mourikis I, Liappas J. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry. 2009;10(1):70-73.
44. Kumar S, Sur S, Singh A. Catatonia following abrupt stoppage of clozapine. Aust N Z J Psychiatry. Jun 2011;45(6):499.
45. England ML, Ongur D, Konopaske GT, Karmacharya R. Catatonia in psychotic patients: clinical features and treatment response. J Neuropsychiatry Clin Neurosci. Spring 2011;23(2):223-226.
46. Hung YY, Yang PS, Huang TL. Clozapine in schizophrenia patients with recurrent catatonia: report of two cases. Psychiatry Clin Neurosci. Apr 2006;60(2):256-258.
47. Perry PJ, Bever KA, Arndt S, Combs MD. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry. Oct 15 1998;44(8):733-738.
48. Dratcu L, Grandison A, McKay G, Bamidele A, Vasudevan V. Clozapine-resistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day. Am J Ther. May-Jun 2007;14(3):314-318.
49. McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry. Jul 1 1999;46(1):125-129.
50. Cormac I, Brown A, Creasey S, Ferriter M, Huckstep B. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr Scand. May 2010;121(5):393-397.
51. Stip E, Lussier I, Ngan E, Mendrek A, Liddle P. Discriminant cognitive factors in responder and nonresponder patients with schizophrenia. Eur Psychiatry. Dec 1999;14(8):442-450.
52. Jacob KS. The quest for the etiology of mental disorders. J Clin Epidemiol. Jan 1994;47(1):97-99.
53. Kendler KS. Toward a philosophical structure for psychiatry. Am J Psychiatry. Mar 2005;162(3):433-440.